The U.S. Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $350,353 definitive contract to Northwestern University, a private research university, for a project related to patient-focused drug development (PFDD) in oncology. This contract was issued under the FDA's Oncology Center of Excellence's PFDD program, which identifies research into measurement of patient experiences. Northwestern University is serving as the prime contractor, with the University of Tasmania as a subcontractor to evaluate a global item for side effect bother. The original contract opportunity was a Broad Agency Announcement (BAA) issued by the FDA to solicit proposals for regulatory science research and development across various areas to support the agency's mission. This BAA is an annual renewal and does not have a set-aside designation.
Generated 6/6/24, 10:28 AM